Drugs / CLN-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03770572 | Nov 2018 → Sep 2029 expected | neuronal ceroid lipofuscinosis 3 | Neela Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLN-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03770572 ↗ |
| Known as | scAAV9.P546.CLN3 | “This is a phase 1/2, open-label, single dose, dose-escalation clinical trial to evaluate the safety and efficacy of CLN-301 (previous NCH Code: scAAV9.P546.CLN3) delivered...” NCT03770572 ↗ |